PubMed:17884841
Annnotations
Glycan-Motif
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 445-459 | https://glytoucan.org/Structures/Glycans/G00054MO | denotes | sialyl Lewis x |
T2 | 461-467 | https://glytoucan.org/Structures/Glycans/G00054MO | denotes | SLe(x) |
T3 | 865-871 | https://glytoucan.org/Structures/Glycans/G00054MO | denotes | SLe(x) |
GlyCosmos6-Glycan-Motif-Image
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 445-459 | Glycan_Motif | denotes | sialyl Lewis x | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00054MO |
T2 | 452-459 | Glycan_Motif | denotes | Lewis x | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G01187XC|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00051MO |
T4 | 461-467 | Glycan_Motif | denotes | SLe(x) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00054MO |
T5 | 865-871 | Glycan_Motif | denotes | SLe(x) | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00054MO |
LitCoin-PubTator-for-Tuning
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1 | 0-14 | DiseaseOrPhenotypicFeature | denotes | Ovarian cancer | MESH:D010051 |
17 | 97-111 | DiseaseOrPhenotypicFeature | denotes | Ovarian cancer | MESH:D010051 |
18 | 138-144 | DiseaseOrPhenotypicFeature | denotes | cancer | MESH:D009369 |
19 | 148-153 | OrganismTaxon | denotes | women | Tax:9606 |
20 | 251-259 | OrganismTaxon | denotes | patients | Tax:9606 |
21 | 274-288 | DiseaseOrPhenotypicFeature | denotes | ovarian cancer | MESH:D010051 |
22 | 427-434 | ChemicalEntity | denotes | glycans | MESH:D011134 |
23 | 436-439 | GeneOrGeneProduct | denotes | FA2 | Gene:2187 |
24 | 722-733 | GeneOrGeneProduct | denotes | haptoglobin | Gene:3240 |
25 | 765-788 | GeneOrGeneProduct | denotes | alpha1-antichymotrypsin | Gene:12 |
26 | 794-802 | OrganismTaxon | denotes | patients | Tax:9606 |
27 | 920-928 | OrganismTaxon | denotes | patients | Tax:9606 |
28 | 958-961 | GeneOrGeneProduct | denotes | FA2 | Gene:2187 |
29 | 1000-1005 | GeneOrGeneProduct | denotes | CA125 | Gene:94025 |
30 | 1270-1284 | DiseaseOrPhenotypicFeature | denotes | ovarian cancer | MESH:D010051 |
31 | 1289-1302 | DiseaseOrPhenotypicFeature | denotes | benign tumors | MESH:D009369 |
LitCoin-Disease-Tuning-1
Id | Subject | Object | Predicate | Lexical cue | ID: |
---|---|---|---|---|---|
T1 | 0-14 | DiseaseOrPhenotypicFeature | denotes | Ovarian cancer | D010051 |
T2 | 97-111 | DiseaseOrPhenotypicFeature | denotes | Ovarian cancer | D010051 |
T3 | 138-144 | DiseaseOrPhenotypicFeature | denotes | cancer | D009369 |
T4 | 274-288 | DiseaseOrPhenotypicFeature | denotes | ovarian cancer | D010051 |
T5 | 318-325 | DiseaseOrPhenotypicFeature | denotes | disease | D004194 |
T6 | 1270-1284 | DiseaseOrPhenotypicFeature | denotes | ovarian cancer | D010051 |
T7 | 1296-1302 | DiseaseOrPhenotypicFeature | denotes | tumors | DISEASE|D009369 |
LitEisuke
Id | Subject | Object | Predicate | Lexical cue | #label |
---|---|---|---|---|---|
T1 | 0-14 | DiseaseOrPhenotypicFeature | denotes | Ovarian cancer | D010051 |
T2 | 97-111 | DiseaseOrPhenotypicFeature | denotes | Ovarian cancer | D010051 |
T3 | 138-144 | DiseaseOrPhenotypicFeature | denotes | cancer | D009369 |
T4 | 274-288 | DiseaseOrPhenotypicFeature | denotes | ovarian cancer | D010051 |
T5 | 1270-1284 | DiseaseOrPhenotypicFeature | denotes | ovarian cancer | D010051 |
T6 | 1296-1302 | DiseaseOrPhenotypicFeature | denotes | tumors | D009369 |
Glycosmos6-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 445-459 | http://www.glycoepitope.jp/epitopes/EP0012 | denotes | sialyl Lewis x |
T2 | 452-459 | http://www.glycoepitope.jp/epitopes/EP0011 | denotes | Lewis x |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-96 | Sentence | denotes | Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. |
TextSentencer_T2 | 97-175 | Sentence | denotes | Ovarian cancer is the fourth most common cancer in women in the Western world. |
TextSentencer_T3 | 176-339 | Sentence | denotes | In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis. |
TextSentencer_T4 | 340-469 | Sentence | denotes | These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x)). |
TextSentencer_T5 | 470-695 | Sentence | denotes | To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (<1 ng protein). |
TextSentencer_T6 | 696-872 | Sentence | denotes | The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x). |
TextSentencer_T7 | 873-993 | Sentence | denotes | We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls. |
TextSentencer_T8 | 994-1149 | Sentence | denotes | Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity. |
TextSentencer_T9 | 1150-1426 | Sentence | denotes | There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw any firm conclusions. |
T1 | 0-96 | Sentence | denotes | Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. |
T2 | 97-175 | Sentence | denotes | Ovarian cancer is the fourth most common cancer in women in the Western world. |
T3 | 176-339 | Sentence | denotes | In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis. |
T4 | 340-469 | Sentence | denotes | These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x)). |
T5 | 470-695 | Sentence | denotes | To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (<1 ng protein). |
T6 | 696-872 | Sentence | denotes | The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x). |
T7 | 873-993 | Sentence | denotes | We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls. |
T8 | 994-1149 | Sentence | denotes | Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity. |
T9 | 1150-1426 | Sentence | denotes | There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw any firm conclusions. |
T1 | 0-96 | Sentence | denotes | Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. |
T2 | 97-175 | Sentence | denotes | Ovarian cancer is the fourth most common cancer in women in the Western world. |
T3 | 176-339 | Sentence | denotes | In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis. |
T4 | 340-469 | Sentence | denotes | These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x)). |
T5 | 470-695 | Sentence | denotes | To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (<1 ng protein). |
T6 | 696-872 | Sentence | denotes | The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x). |
T7 | 873-993 | Sentence | denotes | We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls. |
T8 | 994-1149 | Sentence | denotes | Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity. |
T9 | 1150-1426 | Sentence | denotes | There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw any firm conclusions. |
GlyCosmos6-Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 445-459 | https://glytoucan.org/Structures/Glycans/G00054MO | denotes | sialyl Lewis x |
T2 | 452-459 | https://glytoucan.org/Structures/Glycans/G00051MO | denotes | Lewis x |
T3 | 452-459 | https://glytoucan.org/Structures/Glycans/G01187XC | denotes | Lewis x |
T4 | 461-467 | https://glytoucan.org/Structures/Glycans/G00054MO | denotes | SLe(x) |
T5 | 865-871 | https://glytoucan.org/Structures/Glycans/G00054MO | denotes | SLe(x) |
PubmedHPO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 97-111 | HP_0100615 | denotes | Ovarian cancer |
T2 | 105-111 | HP_0002664 | denotes | cancer |
T3 | 138-144 | HP_0002664 | denotes | cancer |
T4 | 274-288 | HP_0100615 | denotes | ovarian cancer |
T5 | 282-288 | HP_0002664 | denotes | cancer |
T6 | 1270-1284 | HP_0100615 | denotes | ovarian cancer |
T7 | 1278-1284 | HP_0002664 | denotes | cancer |
T8 | 1296-1302 | HP_0002664 | denotes | tumors |
uniprot-human
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 683-685 | http://www.uniprot.org/uniprot/Q92686 | denotes | ng |
T2 | 722-733 | http://www.uniprot.org/uniprot/Q9UC67 | denotes | haptoglobin |
T3 | 1000-1005 | http://www.uniprot.org/uniprot/Q8WXI7 | denotes | CA125 |
uniprot-mouse
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 683-685 | http://www.uniprot.org/uniprot/P60761 | denotes | ng |
T2 | 722-733 | http://www.uniprot.org/uniprot/Q61646 | denotes | haptoglobin |
GlycoBiology-NCBITAXON
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 8-14 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
T2 | 105-111 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
T3 | 138-144 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
T4 | 282-288 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
T5 | 1278-1284 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 45-58 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
T2 | 595-608 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
T3 | 326-338 | http://purl.obolibrary.org/obo/GO_0009405 | denotes | pathogenesis |
T4 | 390-401 | http://purl.obolibrary.org/obo/GO_0036065 | denotes | fucosylated |
T5 | 445-451 | http://purl.obolibrary.org/obo/GO_0097503 | denotes | sialyl |
T6 | 544-553 | http://purl.obolibrary.org/obo/GO_0032502 | denotes | developed |
T7 | 595-619 | http://purl.obolibrary.org/obo/GO_0006486 | denotes | glycosylation of protein |
T8 | 1121-1132 | http://purl.obolibrary.org/obo/GO_0046960 | denotes | sensitivity |
GO-CC
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 385-389 | http://purl.obolibrary.org/obo/GO_0019013 | denotes | core |
UBERON-AE
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 187-192 | http://purl.obolibrary.org/obo/UBERON_0002542 | denotes | scale |
T2 | 234-239 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | serum |
T3 | 1224-1229 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | serum |
GlycoBiology-Motifs
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 445-457 | http://rdf.glycoinfo.org/glycan/G00053MO | denotes | sialyl Lewis |
T2 | 445-459 | http://rdf.glycoinfo.org/glycan/G00054MO | denotes | sialyl Lewis x |
T3 | 452-457 | http://rdf.glycoinfo.org/glycan/G00047MO | denotes | Lewis |
T4 | 452-459 | http://rdf.glycoinfo.org/glycan/G00051MO | denotes | Lewis x |
GlycoBiology-Epitope
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-GlycoEpitope-B_T1 | 452-459 | http://www.glycoepitope.jp/epitopes/EP0011 | denotes | Lewis x |
PD-GlycoEpitope-B_T2 | 445-457 | http://www.glycoepitope.jp/epitopes/EP0008 | denotes | sialyl Lewis |
PD-GlycoEpitope-B_T3 | 445-459 | http://www.glycoepitope.jp/epitopes/EP0012 | denotes | sialyl Lewis x |
performance-test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T1 | 234-239 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | serum |
PD-UBERON-AE-B_T2 | 994-999 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | Serum |
PD-UBERON-AE-B_T3 | 1224-1229 | http://purl.obolibrary.org/obo/UBERON_0001977 | denotes | serum |
PD-UBERON-AE-B_T4 | 187-192 | http://purl.obolibrary.org/obo/UBERON_0002542 | denotes | scale |
mondo_disease
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 0-14 | Disease | denotes | Ovarian cancer | http://purl.obolibrary.org/obo/MONDO_0008170 |
T2 | 97-111 | Disease | denotes | Ovarian cancer | http://purl.obolibrary.org/obo/MONDO_0008170 |
T3 | 138-144 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T4 | 274-288 | Disease | denotes | ovarian cancer | http://purl.obolibrary.org/obo/MONDO_0008170 |
T5 | 436-439 | Disease | denotes | FA2 | http://purl.obolibrary.org/obo/MONDO_0010351 |
T6 | 958-961 | Disease | denotes | FA2 | http://purl.obolibrary.org/obo/MONDO_0010351 |
T7 | 1270-1284 | Disease | denotes | ovarian cancer | http://purl.obolibrary.org/obo/MONDO_0008170 |
T8 | 1289-1302 | Disease | denotes | benign tumors | http://purl.obolibrary.org/obo/MONDO_0005165 |
HP-phenotype
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 0-14 | Phenotype | denotes | Ovarian cancer | HP:0100615 |
T2 | 97-111 | Phenotype | denotes | Ovarian cancer | HP:0100615 |
T3 | 138-144 | Phenotype | denotes | cancer | HP:0002664 |
T4 | 274-288 | Phenotype | denotes | ovarian cancer | HP:0100615 |
T5 | 461-464 | Phenotype | denotes | SLe | HP:0002725 |
T6 | 865-868 | Phenotype | denotes | SLe | HP:0002725 |
T7 | 1270-1284 | Phenotype | denotes | ovarian cancer | HP:0100615 |
Glycan-GlyCosmos
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 445-459 | Glycan | denotes | sialyl Lewis x | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00054MO |
GlyCosmos15-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 0-14 | Phenotype | denotes | Ovarian cancer | HP:0100615 |
T2 | 97-111 | Phenotype | denotes | Ovarian cancer | HP:0100615 |
T3 | 138-144 | Phenotype | denotes | cancer | HP:0002664 |
T4 | 274-288 | Phenotype | denotes | ovarian cancer | HP:0100615 |
T5 | 1270-1284 | Phenotype | denotes | ovarian cancer | HP:0100615 |
GlyCosmos15-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 0-14 | Disease | denotes | Ovarian cancer | http://purl.obolibrary.org/obo/MONDO_0008170 |
T2 | 97-111 | Disease | denotes | Ovarian cancer | http://purl.obolibrary.org/obo/MONDO_0008170 |
T3 | 138-144 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T4 | 274-288 | Disease | denotes | ovarian cancer | http://purl.obolibrary.org/obo/MONDO_0008170 |
T5 | 436-439 | Disease | denotes | FA2 | http://purl.obolibrary.org/obo/MONDO_0010351 |
T6 | 958-961 | Disease | denotes | FA2 | http://purl.obolibrary.org/obo/MONDO_0010351 |
T7 | 1270-1284 | Disease | denotes | ovarian cancer | http://purl.obolibrary.org/obo/MONDO_0008170 |
T8 | 1289-1302 | Disease | denotes | benign tumors | http://purl.obolibrary.org/obo/MONDO_0005165 |
GlyCosmos15-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 187-192 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T2 | 651-656 | Body_part | denotes | spots | http://purl.obolibrary.org/obo/UBERON_2002283 |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-96 | Sentence | denotes | Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. |
TextSentencer_T2 | 97-175 | Sentence | denotes | Ovarian cancer is the fourth most common cancer in women in the Western world. |
TextSentencer_T3 | 176-339 | Sentence | denotes | In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis. |
TextSentencer_T4 | 340-469 | Sentence | denotes | These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x)). |
TextSentencer_T5 | 470-695 | Sentence | denotes | To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (<1 ng protein). |
TextSentencer_T6 | 696-872 | Sentence | denotes | The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x). |
TextSentencer_T7 | 873-993 | Sentence | denotes | We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls. |
TextSentencer_T8 | 994-1149 | Sentence | denotes | Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity. |
TextSentencer_T9 | 1150-1426 | Sentence | denotes | There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw any firm conclusions. |
T1 | 0-96 | Sentence | denotes | Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. |
T2 | 97-175 | Sentence | denotes | Ovarian cancer is the fourth most common cancer in women in the Western world. |
T3 | 176-339 | Sentence | denotes | In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis. |
T4 | 340-469 | Sentence | denotes | These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x)). |
T5 | 470-695 | Sentence | denotes | To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (<1 ng protein). |
T6 | 696-872 | Sentence | denotes | The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x). |
T7 | 873-993 | Sentence | denotes | We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls. |
T8 | 994-1149 | Sentence | denotes | Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity. |
T9 | 1150-1426 | Sentence | denotes | There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw any firm conclusions. |
T1 | 0-96 | Sentence | denotes | Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. |
T2 | 97-175 | Sentence | denotes | Ovarian cancer is the fourth most common cancer in women in the Western world. |
T3 | 176-339 | Sentence | denotes | In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis. |
T4 | 340-469 | Sentence | denotes | These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x)). |
T5 | 470-695 | Sentence | denotes | To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (<1 ng protein). |
T6 | 696-872 | Sentence | denotes | The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x). |
T7 | 873-993 | Sentence | denotes | We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls. |
T8 | 994-1149 | Sentence | denotes | Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity. |
T9 | 1150-1426 | Sentence | denotes | There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw any firm conclusions. |
GlyCosmos15-Sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-96 | Sentence | denotes | Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. |
T2 | 97-175 | Sentence | denotes | Ovarian cancer is the fourth most common cancer in women in the Western world. |
T3 | 176-339 | Sentence | denotes | In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis. |
T4 | 340-469 | Sentence | denotes | These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x)). |
T5 | 470-695 | Sentence | denotes | To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (<1 ng protein). |
T6 | 696-872 | Sentence | denotes | The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x). |
T7 | 873-993 | Sentence | denotes | We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls. |
T8 | 994-1149 | Sentence | denotes | Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity. |
T9 | 1150-1426 | Sentence | denotes | There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw any firm conclusions. |
GlyCosmos15-Glycan
Id | Subject | Object | Predicate | Lexical cue | glycosmos_id | image |
---|---|---|---|---|---|---|
T1 | 445-459 | Glycan | denotes | sialyl Lewis x | https://glycosmos.org/glycans/show/G00054MO | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00054MO |
GlyCosmos15-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
---|---|---|---|---|---|
T1 | 445-459 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | sialyl Lewis x | http://www.glycoepitope.jp/epitopes/EP0012 |
GlyCosmos-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
---|---|---|---|---|---|
T1 | 445-459 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | sialyl Lewis x | http://www.glycoepitope.jp/epitopes/EP0012 |
Anatomy-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 187-192 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T2 | 651-656 | Body_part | denotes | spots | http://purl.obolibrary.org/obo/UBERON_2002283 |